CompletedPHASE1, PHASE2NCT03678259
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
Studying Primary systemic amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Tennessee Graduate School of Medicine
- Principal Investigator
- Jonathan Wall, Ph.D.UTHSC Graduate School of Medicine
- Intervention
- 124I-p5+14 Injection(drug)
- Enrollment
- 57 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2021
Study locations (1)
- University of Tennessee Medical Center, Knoxville, Tennessee, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03678259 on ClinicalTrials.govOther trials for Primary systemic amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06627309Rapid dFLC Response Predict CHR in AL AmyloidosisPeking University People's Hospital
- RECRUITINGNANCT06803082The Impact of Systemic Light Chain Amyloidosis on EyesZhongshan Ophthalmic Center, Sun Yat-sen University
- RECRUITINGNANCT02641145Molecular Imaging of Primary Amyloid CardiomyopathyBrigham and Women's Hospital